Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Nextech3D.ai Announces First New Customer Win For its AI Powered Photography Studio (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Claritas Pharmaceuticals Inc CLAZF

Healthcare Biotechnology
Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID... see more

GREY:CLAZF - Post Discussion

Claritas Pharmaceuticals Inc > MD&A .....!!!
View:
Post by HighSkies2019 on Sep 02, 2021 8:52am

MD&A .....!!!

They have all their financials up to date ..and our balance sheet is clean with our current particulars ...they have a small deficit considering they have multiple products to offer with billion dollar markets ....they have multiple avenues of incoming future money ...AUD refunds...our new financing once confirmed ...20 million more from BARDA and support from health care once phase 1 is complete ...if our R107 NO has what our news release gave us with results from clinical trials required by govt procedures...and the potential to help fight these variants.. Big Parma Buyers are already courting us....testing was already with NO sprays from Sanotize ...our NO formula is supposedly superior with patents in many countries ...shorts beware ..gltal
Comment by Dude51 on Sep 02, 2021 9:57am
Since its inception in July 2014, Claritas has accumulated a deficit of approximately $59.2 million as at June 30, 2021. The Company did not generate any revenue from product sales during the three months period ended June 30, 2021. Claritas expects its operating losses to continue in the next fiscal year as it invests in its product development programs. The Company has funded its operations with ...more  
Claritas Pharmaceuticals Inc